Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2007

View Archived Issues

Study reveals advantages of insulin VIAject over insulin lispro, regular insulin

Tetrodotoxin relieves severe cancer-related pain

UK-500,001 ineffective in asthma, COPD studies

Inhibition of MarA virulence factor increases survival in Pseudomonas aeruginosa pneumonia model

Incyte provides update on positive proof-of-concept results from pipeline

NPS licenses rights to Gattex outside of North America to Nycomed

CombinatoRx begins CRx-102 phase IIb clinical study in knee osteoarthritis

Asentar enters phase II trial in pancreatic cancer and is in ongoing phase III AIPC trial

Series A financing raises USD 20 million for Sequel

OctoPlus acquires worldwide rights to Theratechnologies' GLP-1 analogues

Positive results for SIGA's preclinical trials of ST-246 for smallpox

NexGenix signs worldwide Hsp90 inhibitors agreement with the ULP and CNRS

Palatin provides update on phase II trial of bremelanotide for FSAD

The Medicines Company's sNDA for expanded use of Angiomax accepted by FDA

Update on EMEA submission for Rapinyl for breakthrough cancer pain

Santhera to initiate phase III trial of SNT-MC17 under SPA with FDA

Biomira changes name to Oncothyreon

Preclinical results of VEL-0230, a dual-action cathepsin K inhibitor, reported

Positive preclinical results of the anti-varicella zoster virus agent FV-100

Basilea submits MAA to Swissmedic for oral alitretinoin for CHE

Tanabe Seiyaku and Mitsubishi Pharma merge to form Mitsubishi Tanabe Pharma

FDA approves CSL's influenza vaccine Afluria

EC expands indication of Amgen's Aranesp

Recent patents impart new therapeutic agents for cancer

Once-daily oral antihistamine Xyzal available by prescription in U.S.

New antipsoriatic agents reported by Wisconsin Alumni Research Foundation

Novel histamine H3 receptor ligands reported in recent Abbott patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...